We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ATLAS Biolabs has Licensed Cartagenia Software for Analysis and Interpretation of Genetic Data


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "ATLAS Biolabs has Licensed Cartagenia Software for Analysis and Interpretation of Genetic Data"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
By licensing the Cartagenia BENCH software, ATLAS Biolabs GmbH has expanded its services for the evaluation of genetic data obtained by DNA chip analysis. With the aid of this web-based interpretation software it is possible to screen for disease- and family-specific genetic variations and compare them with public data online. It also provides a database-assisted platform for project-related collaboration between different scientific institutions. Thus, customers of ATLAS Biolabs can easily match genetic data and results.

"We are delighted with this new software,” said Dr. Karsten Heidtke, Head of Bioinformatics at ATLAS Biolabs. “The advantages for our customers are obvious. It provides them with an efficient evaluation system on which they can rely without having to establish their own bioinformatics resources. Cartagenia BENCH processes DNA data from all common chip assay systems including Affymetrix, Agilent and NimbleGen, which are handled at ATLAS Biolabs.”

In addition to academic institutions, centers specialized in human genetic testing and cytogenetic laboratories may benefit particularly from ATLAS Biolabs’ new service.

“In a pilot phase, hundreds of results have already been transferred to the Cartagenia BENCH platform. This tremendously improves our capacity to compare common genetic elements between patients with identical phenotypes," explains Dr. Gundula Thiel, Medical Director of ATLAS Biolabs GmbH and head of a human genetic laboratory in Berlin, Germany.
Advertisement